Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace
On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the opportunity to provide comments on the U.S. Food and Drug Administration’s (FDA) “Facilitating Competition and Innovation in the Biological Products Marketplace.”
The ability to safely substitute FDA-approved biosimilars for reference biologics will be critical to realizing the full cost-savings potential of biosimilars and will ensure that patients have timely access to safe, less-costly therapies. HSCA and its member healthcare group purchasing organizations are committed to lowering costs through increased competition and innovation in the healthcare marketplace and have consistently advocated for policies to ensure a pathway to market for biosimilars that prioritizes patient safety and cost savings.
We applaud the FDA for recognizing the value of a competitive and innovative biosimilars marketplace and respectfully offer the following recommendations to promote the swift uptake of biosimilar products:
Related Posts
HSCA Joins Leading Healthcare Organizations in Supporting the CREATES Act (S.974)
We, the undersigned, commend you for your leadership and commitment to reducing...
HSCA Comments on DEA Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
HSCA Announces Healthcare Cybersecurity Key Considerations
The Healthcare Supply Chain Association (HSCA) today announced the release of key...
HSCA Releases Second Annual Report on Value GPOs Deliver to the Healthcare Supply Chain
Washington, DC (August 21, 2018) – The Healthcare Supply Chain Association...